Targeting the genetic variations of the PI3K/AKT/mTOR pathway has potential use in the treatment of various cancer (Vivanco and Sawyers, 2002[46]; Carneiro et al., 2015[7]; Houede and Pourquier, 2015[21]; Guerrero-Zotano et al., 2016[18]). This evidence concerns the gene PIK3CA and cancer.